On Nov. 23, Chinese biotech firm Baili Tianheng announced that regulators have accepted the New Drug Application for Iza‑bren, an experimental cancer medicine that targets both EGFR and HER3 proteins. Iza‑bren is the world’s only EGFR×HER3 bispecific antibody‑drug conjugate (ADC) in Phase III trials and the first of its kind to reach the NDA stage, aimed at treating nasopharyngeal carcinoma. Iza‑bren is part of a wave of first‑in‑class drugs emerging from China. In the first half of this year, China approved 43 innovative medicines—a 59 % jump from a year earlier—and has now brought more than 210 novel drugs to market over the past five years, accounting for roughly 30 % of the world’s pipeline. Experts say the real test is no longer just getting foreign approvals; it’s about selling these drugs abroad. Recent successes, such as evonesumab—the first PD‑1/VEGF bispecific antibody approved worldwide—show China can lead in complex biologics. Companies like Lishen Medicine, Biomorph, Tonher Biotechnology and others are lining up similar bispecific candidates for overseas deals. Data from PharmCube reveal that China’s licensing‑out revenues have been climbing year‑on‑year since 2022, now outpacing domestic financing. Meanwhile, the Wind Pharmaceutical Index is up 26.7 % and the Hang Seng Healthcare Index has surged nearly 48 % in the first half of 2025, underscoring growing investor confidence in Chinese innovative drugs as they move from lab breakthroughs to global market winners.
Read moreChinese pharmaceutical firms are rapidly becoming global innovators, and the secret lies in a two‑step playbook. First, they perfect “fast‑follow” drugs—safer, better‑dosed versions of existing medicines—before moving on to truly novel therapies that target new disease mechanisms. This approach, combined with a patient pool twice the size of most markets and a dense network of trial sites, cuts the time from discovery to human trials in half the global average. The payoff is evident. International giants are paying billions for Chinese breakthroughs: Pfizer spent $1.25 billion on an experimental cancer drug, GSK locked in a $500 million lung‑disease deal with Hengrui, and Novartis pledged up to $5.2 billion for a cardiovascular therapy. Chinese biotech firms now enjoy a median 7 % return on R&D capital, while U.S. peers hover near zero. A 2015 regulatory overhaul slashed approval times from 501 to 87 days and aligned standards with the West, attracting returning overseas talent (“sea turtles”) who brought financing expertise and global perspectives. Milestones such as BeiGene’s FDA‑approved cancer drug in 2019 and Kangfang Bio’s lung‑cancer success in 2024 signal a shift. With the U.S. facing a massive “patent cliff,” Western companies are hunting for new molecules abroad, and China is delivering, from cutting‑edge antibody‑drug conjugates to next‑generation obesity treatments. The country’s four‑step model—state‑funded research, spin‑out startups, venture backing, and corporate scaling—mirrors the U.S. system and is propelling China to the forefront of drug innovation.
Read more